Radiation Biology: Fractionation in Head and Neck Cancer
A 55-year-old man with locally advanced squamous cell carcinoma of the tonsil (T3N2bM0, HPV-negative) is being considered for definitive chemoradiotherapy. The tumor measures 4.5 cm and has invaded the base of tongue. He has a 30 pack-year smoking history and continues to smoke. The radiation oncology team is debating between conventional fractionation (70 Gy in 35 fractions over 7 weeks) with concurrent cisplatin, and accelerated fractionation with concomitant boost (72 Gy in 42 fractions over 6 weeks) with concurrent cisplatin. The patient is concerned about treatment time and side effects.
1. Explain the radiobiological rationale for accelerated fractionation in this patient.
Read the worked answer
Accelerated fractionation reduces the overall treatment time, which limits tumor repopulation during radiotherapy. Head and neck squamous cell carcinomas have a high potential doubling time, and repopulation accelerates after about 3-4 weeks of treatment. By delivering the same or slightly higher total dose in a shorter time, accelerated fractionation increases the biologically effective dose to the tumor. The concomitant boost technique delivers a second daily fraction to the tumor volume during the last 2-3 weeks, when repopulation is most rapid. This approach has been shown to improve locoregional control compared to conventional fractionation, particularly in HPV-negative patients with a history of smoking, who have a worse prognosis. However, it increases acute mucosal toxicity, requiring supportive care.
2. What are the trade-offs in terms of acute and late toxicity between the two schedules?
Read the worked answer
Conventional fractionation (70 Gy over 7 weeks) with concurrent cisplatin is associated with significant acute mucositis, dysphagia, and dermatitis, but the prolonged overall time allows some mucosal recovery between fractions. Accelerated fractionation with concomitant boost (72 Gy over 6 weeks) delivers more dose per week, leading to more severe acute mucositis, often requiring feeding tube placement and intensive pain management. However, because the total dose per fraction to late-responding tissues is not increased (the boost is given as a second daily fraction with at least 6 hours between fractions), late toxicity is not significantly higher. The risk of severe acute toxicity may necessitate treatment breaks, which could compromise the benefit of acceleration. Patient selection is crucial: those who can tolerate intensive supportive care and have good performance status are suitable. Smoking cessation should be strongly encouraged to improve outcomes and reduce toxicity.